1. Phylogeny  
CDK12 (also known as CRK7, CRKRS, or KIAA0904; UniProt Q9NYV4) is a member of the cyclin‐dependent kinase (CDK) family that specializes in the regulation of transcription rather than cell cycle progression. Phylogenetic analyses have established that CDK12 is evolutionarily conserved across metazoans and can be traced back to the common ancestral kinases present in early eukaryotes. It is considered the metazoan ortholog of the yeast kinase Ctk1 and is closely related to CDK13, with which it shares substantial similarity in the catalytic domain yet displays distinct regulatory and substrate‐targeting features (bosken2014thestructureand pages 1-2, tadesse2021thepromiseand pages 1-2). Within the human kinome, CDK12 is assigned to the transcription‐associated CDKs, a group that includes other kinases responsible for RNA polymerase II (RNAPII) regulation. Unlike cell cycle kinases, these transcriptional CDKs are characterized by extended sequences that include arginine/serine‐rich (RS) domains, believed to have arisen by gene duplication events early in chordate evolution. Comparative studies have revealed that although CDK12 and CDK13 share more than 93% identity in their kinase domains, their overall sequence identity is approximately 43%, which is indicative of evolutionary divergence in regulatory regions responsible for distinct functional outputs (pellarin2025cyclindependentproteinkinases pages 13-14, tadesse2021thepromiseand pages 1-2). This grouping, along with the conservation of key regulatory motifs and interaction with cyclin partners (primarily cyclin K), emphasize CDK12’s integral role within the conserved transcriptional machinery that has been maintained from yeast to humans (xiao2023comingofage pages 3-5, yang2025discoveryofyjz5118 pages 22-24).

2. Reaction Catalyzed  
CDK12 catalyzes the transfer of a phosphate group from ATP to specific serine residues within the heptad repeats of the C-terminal domain (CTD) of RNA polymerase II. The chemical reaction can be summarized as:  
  ATP + [RNAPII CTD] → ADP + [RNAPII CTD]-phosphoserine + H⁺.  
This phosphorylation event is critical for converting the CTD from a state permissive for initiation to one that supports productive transcription elongation and co-transcriptional RNA processing. CDK12 shows a marked preference for phosphorylating the Ser-5 residue in CTD repeats that have been prephosphorylated at Ser-7, although it can also target the Ser-2 residue in these motifs. This reaction is central to the kinase’s role in coupling transcription elongation with mRNA splicing and 3′ end formation (cheng2012interactionofcyclindependent pages 1-2, bayles2019exvivoscreen pages 16-16).

3. Cofactor Requirements  
As with most serine/threonine protein kinases, the enzymatic activity of CDK12 is strictly dependent on the presence of divalent cations. In particular, magnesium ions (Mg²⁺) are required to coordinate binding of ATP within the active site, thereby facilitating the transfer of the phosphate group to the substrate. This dependence on Mg²⁺ is a common characteristic within the CDK family and underpins the mechanistic basis for its catalytic activity (bosken2014thestructureand pages 1-2).

4. Substrate Specificity  
CDK12 exhibits a refined substrate selectivity that is largely defined by the structure of its primary substrate, the RNA polymerase II C-terminal domain (CTD), which consists of tandem repeats of the consensus heptapeptide sequence Y₁S₂P₃T₄S₅P₆S₇. The kinase preferentially phosphorylates the Ser-5 residue in CTD repeats that have undergone prior phosphorylation at Ser-7; under certain conditions, it is also capable of phosphorylating Ser-2. This dual specificity is critical for modulating the dynamic phosphorylation code that governs the progression of transcription elongation and the recruitment of mRNA processing factors. The preference for prephosphorylated CTD substrates suggests an interdependency within the CTD phosphorylation cascade, wherein prior modifications create a favorable conformation or recognition motif for CDK12 activity. In addition to the CTD, CDK12 has been implicated in the phosphorylation of certain splicing regulators, including serine/arginine-rich splicing factor 1 (SRSF1), thereby linking the transcription machinery with splicing control (bosken2014thestructureand pages 1-2, choi2020geneexpressionregulation pages 8-9). Detailed substrate‐mapping studies using global kinase specificity profiling have reinforced the notion that CDK12’s activity is highly dependent on both the local sequence context and pre-existing phosphorylation events within its substrate, thereby ensuring precise regulation of transcription and RNA processing across the genome (pellarin2025cyclindependentproteinkinases pages 23-24).

5. Structure  
CDK12 is an unusually large cyclin‐dependent kinase, with a primary sequence of approximately 1490 amino acids and a molecular mass in the range of 160–170 kDa. The protein displays a modular architecture that includes a central bilobal kinase domain responsible for catalytic activity, flanked by extensive intrinsically disordered regions that harbor regulatory elements. In the N-terminal region, CDK12 contains multiple arginine/serine-rich (RS) motifs that are critical for its subnuclear localization; these motifs facilitate the organization of the kinase within nuclear speckles, which serve as reservoirs for splicing factors and RNA processing proteins (pellarin2025cyclindependentproteinkinases pages 13-14, pluta2024cyclin‐dependentkinasesmasters pages 28-29). The central kinase domain exhibits the hallmark bilobal structure common to protein kinases, featuring an N-lobe predominantly composed of β-sheets and a C-lobe rich in α-helices. Key catalytic features such as the activation loop (T-loop), a conserved C-helix, and hydrophobic spines are all present. Structural studies, including those that have employed co-crystallization with selective inhibitors—such as the 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives—have provided insights into the conformational states of CDK12 when bound to cyclin K (ito2018discoveryof3benzyl1(trans4((5cyanopyridin2yl)amino)cyclohexyl)1arylurea pages 17-18). The kinase domain’s C-terminal extension, which is not found in many other CDKs, contains a histidine-glutamic acid motif followed by a polybasic cluster that appears to enhance substrate recognition and catalytic efficiency (bosken2014thestructureand pages 1-2). Moreover, the association with its regulatory partner, cyclin K (primarily the cyclin K1 isoform), is essential not only for kinase activation but also for proper substrate orientation; the interaction interface between CDK12 and cyclin K has been mapped by mass spectrometry and immunoprecipitation experiments, and it involves conserved cyclin boxes present in cyclin K (cheng2012interactionofcyclindependent pages 4-5, pluta2024cyclin‐dependentkinasesmasters pages 40-41). These features collectively contribute to CDK12’s unique substrate specificity and are thought to be exploited in the design of selective inhibitors that target the kinase in oncological settings.

6. Regulation  
CDK12 activity is tightly regulated through multiple mechanisms that ensure its proper function in transcription and RNA processing. The foremost regulatory mechanism involves its obligatory association with cyclin K, particularly the cyclin K1 isoform, which is necessary for full activation of the kinase. Binding to cyclin K induces conformational changes that properly align the activation loop and the catalytic residues within the kinase domain, thereby enabling efficient ATP binding and phosphoryl transfer (cheng2012interactionofcyclindependent pages 7-9, tadesse2021thepromiseand pages 2-3). In addition, CDK12 contains an RS domain, whose phosphorylation state modulates both its enzymatic activity and its subnuclear localization; phosphorylation within this domain is critical for targeting the kinase to nuclear speckles, where it associates with RNA processing complexes (araki2023targetingpremrnasplicing pages 13-14, pellarin2025cyclindependentproteinkinases pages 52-52). There is evidence from mass spectrometry analyses supporting multiple phosphorylation sites throughout the disordered regions of CDK12, suggesting that dynamic post-translational modifications further fine-tune its activity and interactions with substrates. Some studies have indicated that alterations in CDK12’s phosphorylation status can affect its interaction with chromatin-modifying proteins such as WAC, which in turn may impact histone H2B mono-ubiquitination events that are linked to transcription and DNA repair (chen2024optimizationofapex2 pages 127-132, although this source is from an unidentified journal, it is consistent with findings reported in other studies such as those in Molecular and Cellular Biology). Moreover, emerging evidence suggests that CDK12 activity might also be modulated by targeted degradation strategies; molecular glue degraders and proteolysis-targeting chimeras (PROTACs) have been developed to induce cyclin K degradation, thereby indirectly attenuating CDK12 activity in certain cancer cells (clopper2022chemicalinhibitorsof pages 15-15, tadesse2021thepromiseand pages 22-23). Thus, the regulation of CDK12 involves a combination of cyclin binding, phosphorylation-dependent conformational changes, and possibly ubiquitin-mediated proteolysis, all of which converge to control its role in transcriptional regulation.

7. Function  
CDK12 plays a central role in regulating transcription elongation by phosphorylating the C-terminal domain (CTD) of RNA polymerase II. This phosphorylation event serves as a crucial switch that enables the transition from transcription initiation to elongation and couples the process to co-transcriptional RNA maturation events, including splicing and 3′ end processing. One of the significant biological functions of CDK12 is the maintenance of genomic stability; by regulating the expression of DNA damage response (DDR) genes, including those involved in homologous recombination repair (such as BRCA1), CDK12 ensures efficient repair of DNA double-strand breaks and prevents the accumulation of genomic aberrations (bayles2019exvivoscreen pages 16-16, ekumi2015ovariancarcinomacdk12 pages 11-12). In addition to its central role in DDR, CDK12 is involved in the regulation of RNA splicing. It has been proposed that phosphorylation of splicing factors, including members of the SR protein family such as SRSF1, by CDK12 helps coordinate the coupling between transcription and pre-mRNA splicing (choi2020geneexpressionregulation pages 8-9, araki2023targetingpremrnasplicing pages 13-14). CDK12 is ubiquitously expressed, with its activity being most critical in rapidly proliferating cells, such as cancer cells, where high-fidelity transcription and DNA repair are essential for cell survival. Furthermore, it has been implicated in the regulation of MAP kinase signaling pathways, thereby potentially affecting cellular responses to external stimuli, including the response to estrogen inhibitors (information provided). Collectively, the functional activities of CDK12 in transcription elongation, RNA processing, and DNA repair tie it integrally to the regulation of gene expression programs that are essential for cell survival and genomic integrity (tadesse2021thepromiseand pages 3-5, yang2025discoveryofyjz5118 pages 22-24).

8. Other Comments  
Selective inhibition of CDK12 has emerged as a promising strategy in cancer therapy, owing to its pivotal role in maintaining the expression of DDR genes and genomic stability. Several potent inhibitors, including covalent agents such as THZ531 and analog-sensitive derivatives, have been developed to target CDK12 with high specificity. In addition, molecular glue degraders, which induce the proteasomal degradation of cyclin K and its associated CDK12, represent an innovative therapeutic modality that exploits CDK12’s dependence on its regulatory partner (ito2018discoveryof3benzyl1(trans4((5cyanopyridin2yl)amino)cyclohexyl)1arylurea pages 17-18, clopper2022chemicalinhibitorsof pages 15-15). Mutations in CDK12 are frequently observed in various cancers, notably high-grade serous ovarian carcinoma, breast, and prostate cancers. Such mutations often result in loss-of-function phenotypes that lead to aberrant expression of DNA repair genes and promote genomic instability, thereby providing both a diagnostic marker and a potential target for combination therapies with PARP inhibitors (ekumi2015ovariancarcinomacdk12 pages 11-12, tadesse2021thepromiseand pages 22-23). Furthermore, the differential regulation and substrate specificity between CDK12 and its paralog CDK13 may offer additional avenues for therapeutic intervention, as dual inhibition of these kinases has been shown to affect large subsets of the transcriptome in cancer cells. These aspects underscore the clinical relevance of CDK12 as both a biomarker and a target in oncology, and they motivate continued efforts to refine inhibitor strategies for enhanced specificity and reduced toxicity (bartkowiak2015engineeringananalogsensitive pages 9-9, tadesse2021thepromiseand pages 25-26).

9. References  
bayles2019exvivoscreen pages 16-16; bosken2014thestructureand pages 1-2; cheng2012interactionofcyclindependent pages 1-2; cheng2012interactionofcyclindependent pages 4-5; cheng2012interactionofcyclindependent pages 7-9; choi2020geneexpressionregulation pages 1-2; choi2020geneexpressionregulation pages 8-9; paculova2017theemergingroles pages 1-2; pellarin2025cyclindependentproteinkinases pages 13-14; pellarin2025cyclindependentproteinkinases pages 52-52; pluta2024cyclin‐dependentkinasesmasters pages 28-29; pluta2024cyclin‐dependentkinasesmasters pages 40-41; tadesse2021thepromiseand pages 1-2; tadesse2021thepromiseand pages 2-3; tadesse2021thepromiseand pages 3-5; tadesse2021thepromiseand pages 6-8; tadesse2021thepromiseand pages 22-23; tadesse2021thepromiseand pages 25-26; xiao2023comingofage pages 3-5; yang2025discoveryofyjz5118 pages 22-24; araki2023targetingpremrnasplicing pages 13-14; araki2023targetingpremrnasplicing pages 14-15; araki2023targetingpremrnasplicing pages 15-15; araki2023targetingpremrnasplicing pages 16-16; badjatia2016cyclindependentkinasecrk9 pages 25-26; bartkowiak2015engineeringananalogsensitive pages 9-9; clopper2022chemicalinhibitorsof pages 15-15; ekumi2015ovariancarcinomacdk12 pages 11-12; ito2018discoveryof3benzyl1(trans4((5cyanopyridin2yl)amino)cyclohexyl)1arylurea pages 17-18.

References

1. (bayles2019exvivoscreen pages 16-16): Ian M. Bayles, M. Krajewska, W. D. Pontius, Alina R. Saiakhova, James J. Morrow, C. Bartels, Jim Lu, Zachary J. Faber, Y. Fedorov, Ellen S Hong, J. Karnuta, B. Rubin, Drew J. Adams, R. George, and P. Scacheri. Ex vivo screen identifies cdk12 as a metastatic vulnerability in osteosarcoma. The Journal of clinical investigation, Oct 2019. URL: https://doi.org/10.1172/jci127718, doi:10.1172/jci127718. This article has 40 citations.

2. (bosken2014thestructureand pages 1-2): Christian A. Bösken, Lucas Farnung, Corinna Hintermair, Miriam Merzel Schachter, Karin Vogel-Bachmayr, Dalibor Blazek, Kanchan Anand, Robert P. Fisher, Dirk Eick, and Matthias Geyer. The structure and substrate specificity of human cdk12/cyclin k. Nature Communications, Mar 2014. URL: https://doi.org/10.1038/ncomms4505, doi:10.1038/ncomms4505. This article has 214 citations and is from a highest quality peer-reviewed journal.

3. (cheng2012interactionofcyclindependent pages 1-2): S.-W. Grace Cheng, Michael A. Kuzyk, Annie Moradian, Taka-Aki Ichu, Vicky C.-D. Chang, Jerry F. Tien, Sarah E. Vollett, Malachi Griffith, Marco A. Marra, and Gregg B. Morin. Interaction of cyclin-dependent kinase 12/crkrs with cyclin k1 is required for the phosphorylation of the c-terminal domain of rna polymerase ii. Molecular and Cellular Biology, 32:4691-4704, Nov 2012. URL: https://doi.org/10.1128/mcb.06267-11, doi:10.1128/mcb.06267-11. This article has 126 citations and is from a domain leading peer-reviewed journal.

4. (cheng2012interactionofcyclindependent pages 7-9): S.-W. Grace Cheng, Michael A. Kuzyk, Annie Moradian, Taka-Aki Ichu, Vicky C.-D. Chang, Jerry F. Tien, Sarah E. Vollett, Malachi Griffith, Marco A. Marra, and Gregg B. Morin. Interaction of cyclin-dependent kinase 12/crkrs with cyclin k1 is required for the phosphorylation of the c-terminal domain of rna polymerase ii. Molecular and Cellular Biology, 32:4691-4704, Nov 2012. URL: https://doi.org/10.1128/mcb.06267-11, doi:10.1128/mcb.06267-11. This article has 126 citations and is from a domain leading peer-reviewed journal.

5. (choi2020geneexpressionregulation pages 1-2): Seung Hyuk Choi, Seongjae Kim, and Katherine A. Jones. Gene expression regulation by cdk12: a versatile kinase in cancer with functions beyond ctd phosphorylation. Experimental &amp; Molecular Medicine, 52:762-771, May 2020. URL: https://doi.org/10.1038/s12276-020-0442-9, doi:10.1038/s12276-020-0442-9. This article has 35 citations.

6. (choi2020geneexpressionregulation pages 8-9): Seung Hyuk Choi, Seongjae Kim, and Katherine A. Jones. Gene expression regulation by cdk12: a versatile kinase in cancer with functions beyond ctd phosphorylation. Experimental &amp; Molecular Medicine, 52:762-771, May 2020. URL: https://doi.org/10.1038/s12276-020-0442-9, doi:10.1038/s12276-020-0442-9. This article has 35 citations.

7. (paculova2017theemergingroles pages 1-2): Hana Paculová and Jiří Kohoutek. The emerging roles of cdk12 in tumorigenesis. Cell Division, Oct 2017. URL: https://doi.org/10.1186/s13008-017-0033-x, doi:10.1186/s13008-017-0033-x. This article has 93 citations and is from a peer-reviewed journal.

8. (pellarin2025cyclindependentproteinkinases pages 23-24): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 34 citations and is from a peer-reviewed journal.

9. (pellarin2025cyclindependentproteinkinases pages 52-52): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 34 citations and is from a peer-reviewed journal.

10. (pluta2024cyclin‐dependentkinasesmasters pages 28-29): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

11. (tadesse2021thepromiseand pages 1-2): Solomon Tadesse, Derek R Duckett, and Andrii Monastyrskyi. The promise and current status of cdk12/13 inhibition for the treatment of cancer. Future Medicinal Chemistry, 13:117-141, Dec 2021. URL: https://doi.org/10.4155/fmc-2020-0240, doi:10.4155/fmc-2020-0240. This article has 41 citations and is from a peer-reviewed journal.

12. (tadesse2021thepromiseand pages 2-3): Solomon Tadesse, Derek R Duckett, and Andrii Monastyrskyi. The promise and current status of cdk12/13 inhibition for the treatment of cancer. Future Medicinal Chemistry, 13:117-141, Dec 2021. URL: https://doi.org/10.4155/fmc-2020-0240, doi:10.4155/fmc-2020-0240. This article has 41 citations and is from a peer-reviewed journal.

13. (tadesse2021thepromiseand pages 22-23): Solomon Tadesse, Derek R Duckett, and Andrii Monastyrskyi. The promise and current status of cdk12/13 inhibition for the treatment of cancer. Future Medicinal Chemistry, 13:117-141, Dec 2021. URL: https://doi.org/10.4155/fmc-2020-0240, doi:10.4155/fmc-2020-0240. This article has 41 citations and is from a peer-reviewed journal.

14. (tadesse2021thepromiseand pages 3-5): Solomon Tadesse, Derek R Duckett, and Andrii Monastyrskyi. The promise and current status of cdk12/13 inhibition for the treatment of cancer. Future Medicinal Chemistry, 13:117-141, Dec 2021. URL: https://doi.org/10.4155/fmc-2020-0240, doi:10.4155/fmc-2020-0240. This article has 41 citations and is from a peer-reviewed journal.

15. (tadesse2021thepromiseand pages 6-8): Solomon Tadesse, Derek R Duckett, and Andrii Monastyrskyi. The promise and current status of cdk12/13 inhibition for the treatment of cancer. Future Medicinal Chemistry, 13:117-141, Dec 2021. URL: https://doi.org/10.4155/fmc-2020-0240, doi:10.4155/fmc-2020-0240. This article has 41 citations and is from a peer-reviewed journal.

16. (xiao2023comingofage pages 3-5): Yi Xiao and Jixin Dong. Coming of age: targeting cyclin k in cancers. Cells, 12:2044, Aug 2023. URL: https://doi.org/10.3390/cells12162044, doi:10.3390/cells12162044. This article has 8 citations and is from a peer-reviewed journal.

17. (yang2025discoveryofyjz5118 pages 22-24): Jianzhang Yang, Yu Chang, Kaijie Zhou, Weixue Huang, Jean Ching-Yi Tien, Pujuan Zhang, Wenyan Liu, Licheng Zhou, Yang Zhou, Xiaomei Ren, Rahul Mannan, Somnath Mahapatra, Yuping Zhang, Rudana Hamadeh, Grafton Ervine, Zhen Wang, George Xiaoju Wang, Arul M. Chinnaiyan, and Ke Ding. Discovery of <b>yjz5118</b>: a potent and highly selective irreversible cdk12/13 inhibitor with synergistic effects in combination with akt inhibition. Journal of Medicinal Chemistry, 68:6718-6734, Mar 2025. URL: https://doi.org/10.1021/acs.jmedchem.5c00127, doi:10.1021/acs.jmedchem.5c00127. This article has 0 citations and is from a highest quality peer-reviewed journal.

18. (araki2023targetingpremrnasplicing pages 13-14): Shinsuke Araki, Momoko Ohori, and Masato Yugami. Targeting pre-mrna splicing in cancers: roles, inhibitors, and therapeutic opportunities. Frontiers in Oncology, Jun 2023. URL: https://doi.org/10.3389/fonc.2023.1152087, doi:10.3389/fonc.2023.1152087. This article has 18 citations and is from a peer-reviewed journal.

19. (araki2023targetingpremrnasplicing pages 14-15): Shinsuke Araki, Momoko Ohori, and Masato Yugami. Targeting pre-mrna splicing in cancers: roles, inhibitors, and therapeutic opportunities. Frontiers in Oncology, Jun 2023. URL: https://doi.org/10.3389/fonc.2023.1152087, doi:10.3389/fonc.2023.1152087. This article has 18 citations and is from a peer-reviewed journal.

20. (araki2023targetingpremrnasplicing pages 15-15): Shinsuke Araki, Momoko Ohori, and Masato Yugami. Targeting pre-mrna splicing in cancers: roles, inhibitors, and therapeutic opportunities. Frontiers in Oncology, Jun 2023. URL: https://doi.org/10.3389/fonc.2023.1152087, doi:10.3389/fonc.2023.1152087. This article has 18 citations and is from a peer-reviewed journal.

21. (araki2023targetingpremrnasplicing pages 16-16): Shinsuke Araki, Momoko Ohori, and Masato Yugami. Targeting pre-mrna splicing in cancers: roles, inhibitors, and therapeutic opportunities. Frontiers in Oncology, Jun 2023. URL: https://doi.org/10.3389/fonc.2023.1152087, doi:10.3389/fonc.2023.1152087. This article has 18 citations and is from a peer-reviewed journal.

22. (badjatia2016cyclindependentkinasecrk9 pages 25-26): Nitika Badjatia, Sung Hee Park, Daniela L. Ambrósio, Justin K. Kirkham, and Arthur Günzl. Cyclin-dependent kinase crk9, required for spliced leader trans splicing of pre-mrna in trypanosomes, functions in a complex with a new l-type cyclin and a kinetoplastid-specific protein. PLOS Pathogens, 12:e1005498, Mar 2016. URL: https://doi.org/10.1371/journal.ppat.1005498, doi:10.1371/journal.ppat.1005498. This article has 23 citations and is from a highest quality peer-reviewed journal.

23. (bartkowiak2015engineeringananalogsensitive pages 9-9): Bartlomiej Bartkowiak, Christopher Yan, and Arno L. Greenleaf. Engineering an analog-sensitive cdk12 cell line using crispr/cas. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1849:1179-1187, Sep 2015. URL: https://doi.org/10.1016/j.bbagrm.2015.07.010, doi:10.1016/j.bbagrm.2015.07.010. This article has 53 citations.

24. (chen2024optimizationofapex2 pages 127-132): R Chen. Optimization of apex2 proximity labeling to identify protein interaction partners for cyclin-dependent kinase 12. Unknown journal, 2024.

25. (cheng2012interactionofcyclindependent pages 4-5): S.-W. Grace Cheng, Michael A. Kuzyk, Annie Moradian, Taka-Aki Ichu, Vicky C.-D. Chang, Jerry F. Tien, Sarah E. Vollett, Malachi Griffith, Marco A. Marra, and Gregg B. Morin. Interaction of cyclin-dependent kinase 12/crkrs with cyclin k1 is required for the phosphorylation of the c-terminal domain of rna polymerase ii. Molecular and Cellular Biology, 32:4691-4704, Nov 2012. URL: https://doi.org/10.1128/mcb.06267-11, doi:10.1128/mcb.06267-11. This article has 126 citations and is from a domain leading peer-reviewed journal.

26. (clopper2022chemicalinhibitorsof pages 15-15): Kevin C. Clopper and Dylan J. Taatjes. Chemical inhibitors of transcription-associated kinases. Current Opinion in Chemical Biology, 70:102186, Oct 2022. URL: https://doi.org/10.1016/j.cbpa.2022.102186, doi:10.1016/j.cbpa.2022.102186. This article has 25 citations and is from a peer-reviewed journal.

27. (ekumi2015ovariancarcinomacdk12 pages 11-12): Kingsley M. Ekumi, H. Paculova, Tina Lenasi, Vendula Pospíchalová, C. A. Bösken, J. Rybaríková, V. Bryja, M. Geyer, D. Blazek, and M. Barborič. Ovarian carcinoma cdk12 mutations misregulate expression of dna repair genes via deficient formation and function of the cdk12/cyck complex. Nucleic Acids Research, 43:2575-2589, Feb 2015. URL: https://doi.org/10.1093/nar/gkv101, doi:10.1093/nar/gkv101. This article has 157 citations and is from a highest quality peer-reviewed journal.

28. (ito2018discoveryof3benzyl1(trans4((5cyanopyridin2yl)amino)cyclohexyl)1arylurea pages 17-18): Masahiro Ito, Toshio Tanaka, Akinori Toita, Noriko Uchiyama, Hironori Kokubo, Nao Morishita, Michael G. Klein, Hua Zou, Morio Murakami, Mitsuyo Kondo, Tomoya Sameshima, Shinsuke Araki, Satoshi Endo, Tomohiro Kawamoto, Gregg B. Morin, Samuel A. Aparicio, Atsushi Nakanishi, Hironobu Maezaki, and Yasuhiro Imaeda. Discovery of 3-benzyl-1-(<i>trans</i>-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (cdk12) inhibitors. Journal of Medicinal Chemistry, 61:7710-7728, Aug 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b00683, doi:10.1021/acs.jmedchem.8b00683. This article has 56 citations and is from a highest quality peer-reviewed journal.

29. (pellarin2025cyclindependentproteinkinases pages 13-14): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 34 citations and is from a peer-reviewed journal.

30. (pluta2024cyclin‐dependentkinasesmasters pages 40-41): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

31. (tadesse2021thepromiseand pages 25-26): Solomon Tadesse, Derek R Duckett, and Andrii Monastyrskyi. The promise and current status of cdk12/13 inhibition for the treatment of cancer. Future Medicinal Chemistry, 13:117-141, Dec 2021. URL: https://doi.org/10.4155/fmc-2020-0240, doi:10.4155/fmc-2020-0240. This article has 41 citations and is from a peer-reviewed journal.